It s s Always Something!
|
|
- Ophelia Townsend
- 5 years ago
- Views:
Transcription
1 It s s Always Something! New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D.
2 When Something Is a Brain Tumor Brain tumors aren t rare: there are over 100,000/yr Most originate as other cancers Even the benign ones are bad Some are curable Some are preventable
3 The Most Common Brain Tumor Lung cancer: responsible for the most cancer deaths in women Types: Small cell (70% CNS) Adenocarcinoma (40% CNS) Average survival 4-8 mo.
4 Primary vs. Metastatic Over 100 types Usually don t spread outside the CNS Can be benign Incidence is increasing Glioma is the most common subtype Can be single or multiple Most commonly originate in lung, breast, kidney, melanoma Almost always in other sites Never benign Incidence is increasing Can be single or multiple
5 Primary Brain Tumors: Who Cares? Brain tumors are among the most deadly of all malignancies Comprise only 2% of all cancers Few risk factors known No prevention strategies identified Early detection does not prolong survival
6 Doctor, I think I have a brain tumor Headaches: common but not universal Seizures: often in slowgrowing tumors Memory loss, speech disturbance, loss of balance common Almost impossible to detect early by symptoms alone Symptoms may continue less than 1 mo or more than 10 yrs
7 What Happens Next
8 Primary Brain Tumors Benign: take it out! Malignant: take out what you can (usually) Radiation (sometimes) Chemotherapy (sometimes) As a rule, there are no rules!
9 Current Treatment Strategies in Malignant Glioma After surgical resection, pts complete 6 wks of RT and Temodar Maintenance: Temodar for 6-12 mo. Median survival 17 mo., most relapse Very well tolerated; some long term survivors
10 Radiation Therapy & Knives Whole brain radiation Metastases CNS lymphoma Local RT Most solitary tumors Typically 6 weeks Gamma Knife and Cyberknife Very precise Very small tumors For some non-tumor conditions
11 Cytotoxic Therapy in Malignant Glioma Gliadel wafer, placed into tumor cavity Temodar, at diagnosis or relapse Other options: Carboplatin BCNU/CCNU CPT-11 Procarbazine Etoposide (VP-16) Combinations
12 Gliadel: Chemotherapy Even a Neurosurgeon Could Love Gliadel is a BCNU wafer Gliadel is implanted after surgical resection Gliadel releases BCNU 2-3 weeks Gliadel Takes 15 minutes Adds about 2-3 mo. survival
13 The New Standard of Care Temodar is an oral chemotherapy drug developed in Europe and approved by the FDA in 1999 Most brain tumor pts receive Temodar as their first (and only) chemotherapy Cost: $ /mo.
14 Cytotoxics vs. Targeted May be natural or synthetic May be administered as active agent or prodrug Affect: DNA of rapidly dividing cells Cell enzymes cytoskeleton Include monoclonal antibodies, peptides, cytokines, synthetic nucleic acid sequences May act as: Growth factors Cell-membrane targets Transmembrane targets Cytoplasmic targets Nuclear targets
15 Targeted Therapeutics These agents modify the behavior of the malignant state by modulating abnormal signals Example: agents that block angiogenesis, the proliferation of blood vessels allowing tumor growth At least 600 distinct agents have been clinically evaluated
16 Targets of Approved Drugs CD 20 Her-2/neu Cyclooxygenase-2 DNA polymerase Platelet-derived growth factor Adenosine deaminase Epidermal growth factor receptor P-glycoprotein Vascular endothelial growth factor Estrogen receptor IL-2 receptor Retinoic acid receptor
17 Is There a Brain Tumor Gene? There are over 3,000 genes that have been reported as possible factors in the development of malignant brain tumors Few have been examined as potential targets for therapy
18
19 A New Definition of What Works Cancers may respond by disappearing completely (CR) or by at least 50% of the original size (PR) Because of the aggressiveness of many brain tumors, stable disease (SD) is considered a response Margins of some tumors are difficult to measure, so survival (OS) and 6 mo. progression free survival (PFS) are used
20 VEGF: Why target vascular endothelium? Malignant gliomas are known to overexpress VEGF VEGF is upregulated in the transition from anaplastic astrocytoma to GBM VEGF can be induced by hypoxia
21
22 Avastin is a monoclonal antibody that binds to and inhibits VEGF Avastin has been approved for colon cancer, lung cancer, and breast cancer Genentech initially did not sponsor clinical trials in MG because of the risk of intracranial hemorrhage
23 Avastin: A Ray of Hope? Avastin has been used as a single agent and in combination with CPT-11, Temodar, and other drugs Toxicities include hypertension and epistaxis; >1% of patients develop intracranial hemorrhage; 2% develop bowel perforation
24 Avastin: A Breakthrough?
25 Avastin s Effect on Cerebral Edema Avastin blocks vascular proliferation, decreasing vasogenic edema as well as starving the tumor CT/MRI scans show reduction in enhancement and tumor volume
26 Avastin: Improving Survival? All pts initially treated with Avastin had failed RT and Temodar Pts who had disease progression during RT also responded 90% of patients receiving Avastin had clinical and/or radiographic improvement, typically within 1 month Avastin was FDA approved for recurrent malignant glioma in May 09
27 News from ASCO 2009 American Society of Clinical Oncology Avastin trials in Glioblastoma: Avastin + oral VP-16: 6 mo. PFS 44% Avastin + fotemustine: 33% CR and PR Avastin + CPT-11: 6 mo. PFS 37% Avastin q 3 wks: 6 mo. PFS 32% By comparison: Tarceva + Torisel: 6 mo. PFS 12.5%; no objective responses
28 Cilengitide: the next Avastin? Cilengitide is an integrin inhibitor that has anti-angiogenic and anti-invastive properties Combined with Temodar and RT, showed a 6 mo. PFS of 69% However, when used alone in patients who had failed standard therapy, 6 mo. PFS was 16% Mild side effects: Fatigue, joint aches
29 Brain Tumor Vaccines Dendritic cell vaccines have shown promise when combined with standard therapy Pt s dendritic cells are cultured with pt s tumor cells Dendritic cells are injected SQ over a period of weeks In some studies, survival has doubled
30 The Future of Targeted Therapy Avastin will likely move into first line treatment, in combination with Temodar Cilengitide, AZD2171, Talampanel, all show activity in glioma Vaccines that target EGFR are also proving effective
31 Daria s Case: Primary CNS Lymphoma 42 yo voice teacher, stuttered and stumbled over words Tumor in left temporal area diagnosed 12/05 Surgically removed 6 months of chemotherapy Chance of cure: 70%
32 Gwen s Case: Anaplastic Oligodendroglioma 35 yo marketing VP, had seizure 6/2000 Diagnosis: anaplastic oligodendroglioma Treatment: Surgical resection Radiation to left frontal area Stereotactic radiation boost 2 years of oral chemotherapy Survival: 9 yrs so far
33 Julie s Case: Recurrent Anaplastic Astrocytoma For several years, 30 yo medical transcriptionist, had severe headaches, seizures Surgery 4/2002: anaplastic astrocytoma Had radiation and chemo; tumor returned in 8/2003 Had 4 mo of intra-arterial chemotherapy Has been in remission since 1/2004
34 Dorothy s Case: Refractory Glioblastoma 34 yo diagnosed with glioblastoma 4/2001 Had 3 surgeries, radiation, 6 types of chemotherapy Started Avastin 3/2004 The first person in the world to receive Avastin for a malignant brain tumor
35 Say Yes to Drugs! TO DIE BECAUSE YOUR CARE COSTS The newer drugs are all expensive Insurance won t pay for experimental therapy Medicare and Medicaid also deny payment for many drugs for brain tumors
36 The Ethical Dilemma Is it ever ethical to withhold treatment because of the pt s inability to pay? How much should physicians tell their pts about cost? Can pts truly give informed consent without knowing how $$ affects treatment?
37 On the Road to a Cure Treatment early in the course of the disease may limit spread Approved drugs + drugs in development= 100 s; combinations = s? Agents risk abandonment before thorough study Clinical trials must keep pace with drug discovery
New Approaches in Brain Tumor Treatment. Virginia Stark-Vance, M.D.
New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. The Primary Brain Tumors es for PicturesMCD for 004.JPG 00 Meningioma 30% Glioblastoma 20% Astrocytoma 10% Nerve sheath 8% Pituitary 6%
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More informationCurrent and Future Treatment Options for Glioblastoma
Current and Future Treatment Options for Glioblastoma Santosh Kesari, MD, PhD, FANA, FAAN Chair, Department of Translational Neurosciences and Neurotherapeutics John Wayne Cancer Institute & Pacific Neuroscience
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationMALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
More informationBrain Tumors. Andrew J. Fabiano, MD FAANS. Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine
Brain Tumors Andrew J. Fabiano, MD FAANS Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine Brain Tumors Brain Tumor Basics Types of Tumors Cases Brain
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma
AMERICAN BRAIN TUMOR ASSOCIATION Oligodendroglioma and Oligoastrocytoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the
More informationNeurosurgical Management of Brain Tumours. Nicholas Little Neurosurgeon RNSH
Neurosurgical Management of Brain Tumours Nicholas Little Neurosurgeon RNSH General Most common tumours are metastatic 10x more common than primary Incidence of primary neoplasms is 20 per 100000 per year
More informationFDA APPROVES AVASTIN FOR THE MOST COMMON TYPE OF KIDNEY CANCER
NEWS RELEASE Media Contact: Amy Berry (650) 467-6800 Advocacy Contact: Kristin Reed (650) 467-9831 Investor Contacts: Kathee Littrell (650) 225-1034 Karl Mahler 011 41 61 687 85 03 FDA APPROVES AVASTIN
More informationDouglas Jolly Executive VP R&D Tocagen Inc.
REPLICATING RETROVIRUSES FOR MANIPULATION OF THE TUMOR IMMUNE ECOSYSTEM: PRECLINICAL AND CLINICAL OUTCOMES. Douglas Jolly Executive VP R&D Tocagen Inc. PEGS 2018 IT Track Boston May 1 2018 Outline Phase
More informationX-Plain Brain Cancer Reference Summary
X-Plain Brain Cancer Reference Summary Introduction Brain tumors are not rare. About 20,000 Americans are diagnosed with brain cancer or related cancer of the nervous system. This reference summary will
More informationBrain and Spine Tumors
Brain and Spine Tumors Andrew J. Fabiano, MD FAANS Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine Brain Tumors Brain Tumor Basics Types of Tumors Cases
More informationCPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer
CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer The Harvard community has made this article openly available. Please share how this
More informationNeurosurgery Review. Mudit Sharma, MD May 16 th, 2008
Neurosurgery Review Mudit Sharma, MD May 16 th, 2008 Dr. Mudit Sharma, Neurosurgeon Manassas, Fredericksburg, Virginia http://www.virginiaspinespecialists.com Phone: 1-855-SPINE FIX (774-6334) Fundamentals
More informationLOW GRADE ASTROCYTOMAS
LOW GRADE ASTROCYTOMAS This article was provided to us by David Schiff, MD, Associate Professor of Neurology, Neurosurgery, and Medicine at University of Virginia, Charlottesville. We appreciate his generous
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma
AMERICAN BRAIN TUMOR ASSOCIATION Oligodendroglioma and Oligoastrocytoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the
More informationGlioblastoma: Current Treatment Approach 8/20/2018
Glioblastoma: Current Treatment Approach 8/20/2018 Overview What is Glioblastoma? How is it diagnosed How is it treated? Principles of Treatment Surgery, Radiation, Chemotherapy Current Standard of care
More informationCorporate Medical Policy
Corporate Medical Policy Brachytherapy, Intracavitary Balloon Catheter for Brain Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_intracavitary_balloon_catheter_for_brain_cancer
More informationOligodendrogliomas & Oligoastrocytomas
Oligodendrogliomas & Oligoastrocytomas ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More informationBrain cancer survival rate mayo clinic
Brain cancer survival rate mayo clinic Ed' s Guide to Alternative Therapies. Contents: Acai Berries Acupuncture Artemisinin for cancer Beta-mannan to reverse dysplasia of the cervix Anti-Malignin antibody.
More informationNeuro-oncology Update Andrew Kokkino, MD Medical Director, The Neurosciences Institute at Sacred Heart at Riverbend May 20, 2013
Neuro-oncology Update 2013 Andrew Kokkino, MD Medical Director, The Neurosciences Institute at Sacred Heart at Riverbend May 20, 2013 Case 1 58 year old man with recent facial droop and HA s Thin, cachectic
More informationInnovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials
Innovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology, Biomedical Physics, and Bioengineering Brain Tumor Imaging Laboratory
More informationOff-Label Treatments. Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease. Outline
Off-Label Treatments Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease Jennifer Clarke, MD, MPH Assistant Professor Division of Neuro-Oncology Depts of Neurological
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationUNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
More informationHello and welcome to Patient Power sponsored by Northwestern Memorial Hospital. I'm Andrew Schorr.
Brain Tumor Clinical Trials Webcast November 22, 2011 Sean Grimm, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern Memorial Hospital, its medical
More informationOutstanding Questions from Webinar: Long-Term Survival Outcomes for LGG Patients, May 5 th, 2014
Outstanding Questions from Webinar: Long-Term Survival Outcomes for LGG Patients, May 5 th, 2014 Answers provided as a courtesy by Dana Farber Cancer Institute experts: Dr. Mark Kieran Dr. Peter Manley
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationProtocol Abstract and Schema
Protocol Abstract and Schema Phase II study of Bevacizumab plus Irinotecan (Camptosar ) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas,
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationDurable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
More informationGlioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) *Neurosurgery Consultant, King Saud University, Riyadh, KSA *Adjunct Teaching Faculty, Neurosurgery, Stanford School Of Medicine,
More informationTania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015
Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015 Most common brain tumor, affecting 8.5-15% of cancer patients. Treatment options: Whole brain radiation
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationMedia Release. Basel, 17 November 2012
Media Release Basel, 17 November 2012 Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy
More informationCNS TUMORS. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
CNS TUMORS D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) CNS TUMORS The annual incidence of intracranial tumors of the CNS ISmore than intraspinal tumors May be Primary or Secondary
More informationNEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationOutline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationClinical Policy: Temozolomide (Temodar) Reference Number: ERX.SPA.138 Effective Date:
Clinical Policy: (Temodar) Reference Number: ERX.SPA.138 Effective Date: 03.01.14 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAlleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?
Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationClinical Trials for Adult Brain Tumors - the Imaging Perspective
Clinical Trials for Adult Brain Tumors - the Imaging Perspective Whitney B. Pope, M.D., Ph.D. Department of Radiology David Geffen School of Medicine at UCLA August 22, 2015 1 Disclosure of Financial Relationships
More informationMedia Release. Basel, 17 May 2018
Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly
More informationBrain Tumor Treatment
Scan for mobile link. Brain Tumor Treatment Brain Tumors Overview A brain tumor is a group of abnormal cells that grows in or around the brain. Tumors can directly destroy healthy brain cells. They can
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationCILENT P Leblond, DIPG Meeting, Barcelone 2012
CILENT-0902 Cilengitide (EMD121974) in combination with irradiation in children and adolescents with newly diagnosed diffuse intrinsic brainstem glioma : Phase I Study P Leblond, DIPG Meeting, Barcelone
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationIs it cost-effective to treat brain metastasis with advanced technology?
Is it cost-effective to treat brain metastasis with advanced technology? Cost-effectiveness analysis of whole brain RT, stereotactic radiosurgery and craniotomy in HA setting Lam, Tai-Chung, Choi CW Horace,
More informationTargeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009
Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More informationDurable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment
Durable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S
More informationDiscover the facts about
Avastin is approved to treat metastatic colorectal cancer (mcrc) for: First- or second-line treatment in combination with intravenous 5-fluorouracil based chemotherapy Second-line treatment when used with
More informationHighlights from the 2009 Annual Meeting of the American Society of Clinical Oncology. 20 Combination Treatments for Glioblastoma
BRAIN CANCER 18 Brain Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Henry S. Friedman, MD Duke University Medical Center Durham, North Carolina 20
More informationOncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013
Oncological Management of Brain Tumours Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013 Outline General considerations of Primary Brain Tumours: epidemiology, pathology, presentation. Diagnosis
More informationIs Bevacizumab (Avastin) Safe and Effective as Adjuvant Chemotherapy for Adult Patients With Stage IIIb or IV Non-Small Cell Lung Carcinoma (NSCLC)?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Bevacizumab (Avastin) Safe and Effective
More informationIMMUNOTHERAPY FOR LUNG CANCER
IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationThe Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationStereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13
Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall
More informationGlioblastoma multiforme has been described as. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases
» This article has been updated from its originally published version to correct units of measure. See the corresponding erratum notice, DOI: 10.3171/2017.8.JNS08268a. «J Neurosurg 108:000 000, 109:268
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor_treatment_fields_therapy 9/2013 11/2017 11/2018 6/2018 Description of Procedure or Service Tumor-treatment
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationUnderstanding. BrainTumors. Glioblastoma Multiforme NATIONAL BRAIN TUMOR FOUNDATION INFORMATION LINE: CURE GIVING HELP, GIVING HOPE
Understanding BrainTumors Glioblastoma Multiforme NATIONAL BRAIN TUMOR FOUNDATION GIVING HELP, GIVING HOPE INFORMATION LINE: 800.934.CURE 1 1 Understanding BrainTumors Glioblastoma Multiforme NATIONAL
More informationNewly diagnosed with metatastic disease: where do we go from here? Rick Michaelson Saint Barnabas Medical Center
Newly diagnosed with metatastic disease: where do we go from here? Rick Michaelson Saint Barnabas Medical Center A Diagnosis of Advanced Breast Cancer Leads To Many Immediate Questions How am I supposed
More informationMRS and Perfusion of Brain Tumors
Department of Radiology University of California San Diego MRS and Perfusion of Brain Tumors John R. Hesselink, M.D. MRS & Perfusion of Brain Tumors Tumor histology Degree of malignancy Delineate tumor
More informationColorectal Cancer Therapy and Associated Toxicity
Colorectal Cancer Therapy and Associated Toxicity Mountain States Cancer Conference November 6, 2010 Colin D. Weekes, M.D., Ph.D Assistant Professor University of Colorado GI Cancers Are Common 2009 Estimated
More informationExamining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
More informationCURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION *
CURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION * Alessandro Olivi, MD, Jaishri Blakeley, MD, and Allen K. Sills, MD, FACS ABSTRACT The management of glioma
More informationCoQ10 and Cancer Treatment
http://www.lef.org/ Life Extension Magazine September 2009 CoQ10 and Cancer Treatment By William Faloon For more than a decade, Life Extension has reported on small clinical studies that demonstrate beneficial
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationIVC History, Cancer Research
Riordan Clinic IVC Academy 5 IVC History, Cancer Research O (slides 81-116) Cytokine Signaling Categories Heal the Wound! Angiogenesis - 62 Inflammation - 69 Differentiation - 53 Oncogene-Activation -
More informationManagement of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS
Management of Glioma: The Basics Glioma Update 3 oger Stupp, MD Department of Oncology & Cancer Center University Hospital Zurich, Switzerland (roger.stupp@usz.ch) Bern, 3. August 3 The clinical challenge
More informationBreast Cancer: Who Gets It? Who Survives? The Latest Information
Breast Cancer: Who Gets It? Who Survives? The Latest Information James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine
More informationTumors of the Nervous System
Tumors of the Nervous System Peter Canoll MD. PhD. What I want to cover What are the most common types of brain tumors? Who gets them? How do they present? What do they look like? How do they behave? 1
More informationCritical Clinical Updates
Critical Clinical Updates ASTRO Spring Refresher Course JW Marriott Hotel Ramesh Rengan MD PhD Department of Radiation Oncology Friday March 22, 2013 Learning Objectives At the conclusion of this activity,
More informationCarmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
More informationAvastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
More informationHow genetic & biochemical alterations in brain tumors contribute to epileptogenesis
How genetic & biochemical alterations in brain tumors contribute to epileptogenesis December 2 nd, 2012 Joon H. Uhm, MD FRCPC Departments of Neurology & Oncology Mayo Clinic, Rochester, MN American Epilepsy
More informationDr Eddie Mee. Neurosurgeon Auckland City Hospital, Ascot Integrated Hospital, MercyAscot Hospitals, Auckland
Dr Eddie Mee Neurosurgeon Auckland City Hospital, Ascot Integrated Hospital, MercyAscot Hospitals, Auckland 16:30-17:25 WS #48: Current Management of Brain Bleeds and Tumours 17:35-18:30 WS #58: Current
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationIntravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue
Intravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue Tobias Walbert, 1 Daniela Bota, 2 Michael A Vogelbaum, 3 Steven
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationMedia Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011
Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived
More informationFrankly Speaking About Cancer Clinical Trials
Frankly Speaking About Cancer Clinical Trials Medical Review The following slides were medically reviewed by Brad Hirsch, MD, in March 2017. Workshop Overview What is a clinical trial? Why clinical trials
More informationAdvancements in Neuro- Oncology
Advancements in Neuro- Oncology Ricky Chen, MD Director, Neuro-Oncology Providence St Vincent Medical Center November 30 th, 2018 No disclosures Recognizing a brain tumor New and *Persistent Headaches*
More information